Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | XMT-2056 |
Trade Name | |
Synonyms | XMT2056|XMT 2056 |
Drug Descriptions |
XMT-2056 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody conjugated to a STING agonist, which potentially induces an anti-tumor immune response and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3503). |
DrugClasses | HER2 (ERBB2) Antibody 76 HER2 (ERBB2) Antibody-Drug Conjugate 31 STING1 Agonist 19 |
CAS Registry Number | NA |
NCIT ID | C190297 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pertuzumab + XMT-2056 | Pertuzumab XMT-2056 | 0 | 0 |
Trastuzumab + XMT-2056 | Trastuzumab XMT-2056 | 0 | 0 |
XMT-2056 | XMT-2056 | 0 | 1 |